The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6

European Journal of Clinical Pharmacology

Volumn 63, Issue 4, 2007, Pages 345-353

  Nakao, Masashi ^a   Muramoto, Yousuke ^a   Hisadome, Motoko ^a   Yamano, Naoko ^a   Shoji, Mami ^a   Fukushima, Yumi ^b   Saruwatari, Junji ^a   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Co administered medication; Herb drug interaction; Pharmacokinetic interaction

Indexed keywords

3 METHOXYMORPHINAN; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; SHO SEIRYU TO; TJ 19; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HERB DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; OPEN STUDY; PHENOTYPE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; URINALYSIS; WILD TYPE;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUGS, CHINESE HERBAL; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; XANTHINE OXIDASE;

EID: 33947173685     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0253-5     Document Type: Article

References (50)

1. Amagaya S, Iizuka A, Makino B, Kubo M, Komatsu Y, Cheng FC, Ruo TI, Itoh T, Terasawa K (2001) General pharmacological properties of Sho-seiryu-to (TJ-19) extracts. Phytomedicine 8:338-347
2. Bent S, Tiedt TN, Odden MC, Shlipak MG (2003) The relative safety of ephedra compared with other herbal products. Ann Intern Med 138:468-471
3. Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD (2001) Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest 120:1461-1467
4. Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C (2002) Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther 72:514-523
5. Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC (2001) In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 29:1023-1028
6. Chen MF, Shimada F, Kato H, Yano S, Kaneoka M (1991) Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone. Endocrinol Jpn 38:167-174
7. Chen ZR, Somogyi AA, Bochner F (1990) Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 12:97-104
8. Chung JG, Chang HL, Lin WC, Wang HH, Yeh CC, Hung CF, Li YC (2000) Inhibition of N-acetyltransferase activity and DNA-2-aminofluorene adducts by glycyrrhizic acid in human colon tumour cells. Food Chem Toxicol 38:163-172
9. Ducharme J, Abdullah S, Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr 678:113-128
10. Ernst E (2000) Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol 56:523-524
11. Ferrari P, Sansonnens A, Dick B, Frey FJ (2001) In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension 38:1330-1336
12. Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM (2005) Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 61:821-829
13. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD (2004) The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75:89-100
14. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A (2005) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415-412
15. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72:276-287
16. Hasegawa A, Yoshino M, Nakamura H, Ishii I, Watanabe T, Kiuchi M, Ishikawa T, Ohmori S, Kitada M (2002) Identification of inhibitory component in cinnamon - O-methoxycinnamaldehyde inhibits CYP1A2 and CYP2E1. Drug Metab Pharmacokinet 17:229-236
17. Homma M, Oka K, Ikeshima K, Takahashi N, Niitsuma T, Fukuda T, Itoh H (1995) Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. J Pharm Pharmacol 47:687-692
18. Hoskins JM, Shenfield GM, Gross AS (1997) Modified highperformance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping. J Chromatogr 696:81-87
19. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T (2004) Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 32:1351-1358
20. Izzo AA (2004) Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 19:1-16
21. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204
22. Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD (1996) Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 60:374-384
23. Jones DR, Gorski JC, HammanMA, Hall SD (1996) Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr 678:105-111
24. Kalow W, Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519
25. Kao ST, Lin CS, Hsieh CC, Hsieh WT, Lin JG (2001) Effects of xiao-qing-long-tang (XQLT) on bronchoconstriction and airway eosinophil infiltration in ovalbumin-sensitized guinea pigs: in vivo and in vitro studies. Allergy 56:1164-1171
26. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, Bertino JS Jr (1999) Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics 9:453-462
27. Kent UM, Aviram M, Rosenblat M, Hollenberg PF (2002) The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 30:709-715
28. Ko E, Rho S, Cho C, Choi H, Ko S, Lee Y, Hong MC, Shin MK, Jung SG, Bae H (2004) So-Cheong-Ryong-Tang, tradititional Korean medicine, suppresses Th2 lineage development. Biol Pharm Bull 27:739-743
29. Komaki Y, Sugiura H, Koarai A, Tomaki M, Ogawa H, Akita T, Hattori T, Ichinose M (2005) Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways. Pulm Pharmacol Ther 18:297-302
30. Kong LD, Zhang Y, Pan X, Tan RX, Cheng CH (2000) Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Cell Mol Life Sci 57:500-505
31. Kubota T, Yamadura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34
32. Magee KA (2005) Herbal therapy: a review of potential health risks and medicinal interactions. Orthod Craniofac Res 8:60-74
33. Markowitz JS, Donovan JL, Devane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD (2003) Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 74:536-542
34. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68:356-366
35. Min DI, Ku YM, Vichiendilokkul A, Fleckenstein LL (1999) A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy 19:753-759
36. Nacak M, Aynacioglu AS, Filiz A, Cascorbi I, Erdal ME, Yilmaz N, Ekinci E, Roots I (2002) Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol 54:671-674
37. Paolini M, Barillari J, Broccoli M, Pozzetti L, Perocco P, Cantelli-Forti G (1999) Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. Cancer Lett 145:35-42
38. Paolini M, Pozzetti L, Sapone A, Cantelli-Forti G (1998) Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci 62:571-582
39. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H, Kamataki T, Ishizaki T (2002) A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther 72:200-208
40. Saruwatari J, Nakagawa K, Shindo J, Nachi S, Echizen H, Ishizaki T (2003) The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. J Pharm Pharmacol 55:1553-1559
41. Saruwatari J, Matsunaga M, Ikeda K, MS, Nakao M, Oniki K, Seo T, Mihara S, Marubayashi T, MD, Kamataki T, Nakagawa K (2006) Impact of CYP2D6*10 on the H1-antihistamine induced hypersomnia. Eur J Clin Pharmacol (in press)
42. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, Katada J, Hashimoto M, Matsui H, Taki K, Kaminuma T, Yamamoto M, Aida Y, Ohashi A, Ozawa N (2003) Bioinformatics research on inter-racial difference in drug metabolism I, Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48-70
43. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223
44. Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216
45. Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18:1071-1080
46. Usia T, Iwata H, Hiratsuka A, Watabe T, Kadota S, Tezuka Y (2004) Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities. J Nat Prod 67:1079-1083
47. Wennerholm A, Allqvist A, Svensson JO, Gustafsson LL, Mirghani RA, Bertilsson L (2005) Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol 61:113-118
48. Yang J, Peng RX, Kong R, Yu JP (2001) Effects of 18 alpha-glycyrrhizic acid on rat liver cytochrome P450 isoenzymes and phase II transferase. Yao Xue Xue Bao 36:321-324
49. Yu A, Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520
50. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW (2003) Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35-98